252 related articles for article (PubMed ID: 34199285)
21. Myeloma-derived extracellular vesicles mediate HGF/c-Met signaling in osteoblast-like cells.
Strømme O; Psonka-Antonczyk KM; Stokke BT; Sundan A; Arum CJ; Brede G
Exp Cell Res; 2019 Oct; 383(1):111490. PubMed ID: 31283912
[TBL] [Abstract][Full Text] [Related]
22. Extracellular Vesicle microRNAs Contribute to the Osteogenic Inhibition of Mesenchymal Stem Cells in Multiple Myeloma.
Raimondo S; Urzì O; Conigliaro A; Bosco GL; Parisi S; Carlisi M; Siragusa S; Raimondi L; Luca A; Giavaresi G; Alessandro R
Cancers (Basel); 2020 Feb; 12(2):. PubMed ID: 32075123
[TBL] [Abstract][Full Text] [Related]
23. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
Chung C
Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
[TBL] [Abstract][Full Text] [Related]
24. Novel Insights in Anti-CD38 Therapy Based on CD38-Receptor Expression and Function: The Multiple Myeloma Model.
Zannetti BA; Faini AC; Massari E; Geuna M; Maffini E; Poletti G; Cerchione C; Martinelli G; Malavasi F; Lanza F
Cells; 2020 Dec; 9(12):. PubMed ID: 33322499
[TBL] [Abstract][Full Text] [Related]
25. Exosomes play a role in multiple myeloma bone disease and tumor development by targeting osteoclasts and osteoblasts.
Faict S; Muller J; De Veirman K; De Bruyne E; Maes K; Vrancken L; Heusschen R; De Raeve H; Schots R; Vanderkerken K; Caers J; Menu E
Blood Cancer J; 2018 Nov; 8(11):105. PubMed ID: 30409995
[TBL] [Abstract][Full Text] [Related]
26. Targeting of CD38 by the Tumor Suppressor miR-26a Serves as a Novel Potential Therapeutic Agent in Multiple Myeloma.
Hu Y; Liu H; Fang C; Li C; Xhyliu F; Dysert H; Bodo J; Habermehl G; Russell BE; Li W; Chappell M; Jiang X; Ondrejka SL; Hsi ED; Maciejewski JP; Yi Q; Anderson KC; Munshi NC; Ao G; Valent JN; Lin J; Zhao J
Cancer Res; 2020 May; 80(10):2031-2044. PubMed ID: 32193289
[TBL] [Abstract][Full Text] [Related]
27. Exosomes in the Pathogenesis and Treatment of Multiple Myeloma in the Context of the Bone Marrow Microenvironment.
Chen T; Moscvin M; Bianchi G
Front Oncol; 2020; 10():608815. PubMed ID: 33251153
[TBL] [Abstract][Full Text] [Related]
28. Multiple Myeloma Cell-Derived Exosomes: Implications on Tumorigenesis, Diagnosis, Prognosis and Therapeutic Strategies.
Allegra A; Di Gioacchino M; Tonacci A; Petrarca C; Musolino C; Gangemi S
Cells; 2021 Oct; 10(11):. PubMed ID: 34831088
[TBL] [Abstract][Full Text] [Related]
29. CD38 targeted treatment for multiple myeloma.
Jelínek T; Mihályová J; Hájek R
Vnitr Lek; 2018; 64(10):939-948. PubMed ID: 30590941
[TBL] [Abstract][Full Text] [Related]
30. Reprint of "Immunomodulatory effects of CD38-targeting antibodies".
van de Donk NWCJ
Immunol Lett; 2019 Jan; 205():71-77. PubMed ID: 30826127
[TBL] [Abstract][Full Text] [Related]
31. An update on extracellular vesicles in multiple myeloma: a focus on their role in cell-to-cell cross-talk and as potential liquid biopsy biomarkers.
De Luca L; Laurenzana I; Trino S; Lamorte D; Caivano A; Musto P
Expert Rev Mol Diagn; 2019 Mar; 19(3):249-258. PubMed ID: 30782029
[TBL] [Abstract][Full Text] [Related]
32. Osteoblast-Derived Extracellular Vesicles Are Biological Tools for the Delivery of Active Molecules to Bone.
Cappariello A; Loftus A; Muraca M; Maurizi A; Rucci N; Teti A
J Bone Miner Res; 2018 Mar; 33(3):517-533. PubMed ID: 29091316
[TBL] [Abstract][Full Text] [Related]
33. Effects of extracellular vesicle-derived noncoding RNAs on pre-metastatic niche and tumor progression.
Chen Z; Wang Q; Liu J; Wang W; Yuan W; Liu Y; Sun Z; Wang C
Genes Dis; 2024 Jan; 11(1):176-188. PubMed ID: 37588211
[TBL] [Abstract][Full Text] [Related]
34. Controversy in the Use of CD38 Antibody for Treatment of Myeloma: Is High CD38 Expression Good or Bad?
Plesner T; van de Donk N; Richardson PG
Cells; 2020 Feb; 9(2):. PubMed ID: 32041300
[TBL] [Abstract][Full Text] [Related]
35. Role of the bone marrow microenvironment in multiple myeloma.
Roodman GD
J Bone Miner Res; 2002 Nov; 17(11):1921-5. PubMed ID: 12412796
[TBL] [Abstract][Full Text] [Related]
36. Immunomodulatory effects of CD38-targeting antibodies.
van de Donk NWCJ
Immunol Lett; 2018 Jul; 199():16-22. PubMed ID: 29702148
[TBL] [Abstract][Full Text] [Related]
37. Monocyte-derived extracellular vesicles stimulate cytokine secretion and gene expression of matrix metalloproteinases by mesenchymal stem/stromal cells.
Gebraad A; Kornilov R; Kaur S; Miettinen S; Haimi S; Peltoniemi H; Mannerström B; Seppänen-Kaijansinkko R
FEBS J; 2018 Jun; 285(12):2337-2359. PubMed ID: 29732732
[TBL] [Abstract][Full Text] [Related]
38. Bone Marrow Microenvironment Interplay and Current Clinical Practice in Multiple Myeloma: A Review of the Balkan Myeloma Study Group.
Bila J; Katodritou E; Guenova M; Basic-Kinda S; Coriu D; Dapcevic M; Ibricevic-Balic L; Ivanaj A; Karanfilski O; Zver S; Beksac M; Terpos E; Dimopoulos MA
J Clin Med; 2021 Aug; 10(17):. PubMed ID: 34501388
[TBL] [Abstract][Full Text] [Related]
39. Adenosinergic Immunosuppression by Human Mesenchymal Stromal Cells Requires Co-Operation with T cells.
Kerkelä E; Laitinen A; Räbinä J; Valkonen S; Takatalo M; Larjo A; Veijola J; Lampinen M; Siljander P; Lehenkari P; Alfthan K; Laitinen S
Stem Cells; 2016 Mar; 34(3):781-90. PubMed ID: 26731338
[TBL] [Abstract][Full Text] [Related]
40. Emerging Insights on the Biological Impact of Extracellular Vesicle-Associated ncRNAs in Multiple Myeloma.
Raimondo S; Urzì O; Conigliaro A; Raimondi L; Amodio N; Alessandro R
Noncoding RNA; 2020 Aug; 6(3):. PubMed ID: 32764460
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
